DB16437ExperimentalVaccines
The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO® . By teaming up with... By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose.
What you can answer from here — as of April 02, 2025
Which companies are running trials of V590, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account